Overexpression of BASP1 Indicates a Poor Prognosis in Head and Neck Squamous Cell Carcinoma

Brain abundant membrane attached signal protein 1 (BASP1) was originally identified as a membrane and cytoplasmic protein. Recent studies have shown that BASP1 highly expressed in cancer and promoted the proliferation of cancer. However, the role of BASP1 in head and neck squamous cell carcinoma (HN...

Full description

Saved in:
Bibliographic Details
Published inAsian Pacific journal of cancer prevention : APJCP Vol. 21; no. 11; pp. 3435 - 3439
Main Authors Jaikumarr Ram, Ashwin, Girija As, Smiline, Jayaseelan, Vijayashree Priyadharsini, Arumugam, Paramasivam
Format Journal Article
LanguageEnglish
Published Thailand West Asia Organization for Cancer Prevention 01.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Brain abundant membrane attached signal protein 1 (BASP1) was originally identified as a membrane and cytoplasmic protein. Recent studies have shown that BASP1 highly expressed in cancer and promoted the proliferation of cancer. However, the role of BASP1 in head and neck squamous cell carcinoma (HNSCC) is largely unknown.  Here, we performed a systematic data analysis to examine whether BASP1 can function as prognostic marker in HNSCC. In this study, we used Oncomine, and UALCAN, databases to analyze the expression of BASP1 in HNSCC. We used Kaplan-Meier plotter to evaluate the effect of BASP1 on clinical prognosis. In addition, we also analyzed genetic alterations, interaction network, and functional enrichment of BASP1. BASP1 mRNA expression level was remarkably increased in HNSCC than in normal tissues (P=1.624e-12). Moreover, high BASP1 expression was significantly related to poor survival (p=0.00056) in HNSCC patients. In addition, BASP1 gene amplified in 5% of HNSCC patients which contributes to the overexpression of BASP1. These findings suggest that BASP1 was frequently amplified which contributes to the overexpression of BASP1, thereby promoting HNSCC progression. Thus, these results indicate that BASP1 might serve as a biomarker to predict the progression and prognosis of HNSCC patients.
ISSN:1513-7368
2476-762X
DOI:10.31557/APJCP.2020.21.11.3435